Unveiling the myxofibrosarcoma tumor microenvironment: implications for immunotherapy

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Myxofibrosarcoma (MFS) is an aggressive soft tissue sarcoma with high recurrence rates and limited treatment options.
• The tumor microenvironment (TME) in sarcomas, including MFS, is increasingly recognized for its role in disease progression and therapeutic response.
• Limited data exist on the immune landscape of MFS, necessitating further investigation into immune-related biomarkers.

Purpose of the Study:

• To review the cellular and molecular characteristics of the immune infiltration within the MFS tumor microenvironment.
• To assess the prognostic and predictive value of immune biomarkers, including immune checkpoint molecules, tumor-infiltrating lymphocytes, antigen presentation, and angiogenesis.
• To explore potential immunotherapeutic strategies targeting the immune-vascular niche in MFS.

Main Methods:

• Literature review focusing on studies investigating the tumor microenvironment in Myxofibrosarcoma.
• Analysis of existing data on immune checkpoint molecule expression (PD-1, PD-L1), tumor-infiltrating lymphocytes, antigen presentation pathways, and angiogenic signatures in MFS.
• Examination of ongoing clinical trials related to immunomodulation in sarcoma.

Main Results:

• Myxofibrosarcoma exhibits a heterogeneous immune landscape with variable expression of immune checkpoints like PD-1 and PD-L1.
• The presence of tumor-infiltrating lymphocytes, alterations in antigen presentation, and a significant angiogenic signature are noted features.
• These immune and vascular characteristics suggest potential as prognostic and predictive biomarkers.

Conclusions:

• The immune microenvironment of Myxofibrosarcoma holds significant potential for clinical stratification and the development of novel immunotherapeutic approaches.
• Modulating the immune-vascular niche presents a promising avenue for innovative therapeutic strategies in advanced Myxofibrosarcoma.
• Further research into immune biomarkers is crucial for advancing treatment options for this challenging sarcoma subtype.